88 pending office actions • 14 clients
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 19389403 | Untitled | Novartis AG | CARTER, SANDRA DILLAHUNT | 1674 | Non-Final OA | |
| 19389528 | Untitled | Novartis AG | JIANG, DONG | 1674 | Non-Final OA | |
| 19240908 | METHOD OF TREATING PROSTATE CANCER | Novartis AG | PERREIRA, MELISSA JEAN | 1618 | Final Rejection | Jun 17, 2025 |
| 19234864 | STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | Novartis AG | MEJIAS, SAMANTHA LEE | 1618 | Non-Final OA | Jun 11, 2025 |
| 19176436 | PHARMACEUTICAL COMPOSITIONS OF RIBOCICLIB | Novartis AG | YOUNG, MICAH PAUL | 1618 | Non-Final OA | Apr 11, 2025 |
| 19084265 | Stable, concentrated radionuclide complex solutions | Advanced Accelerator Applications SA | PERREIRA, MELISSA JEAN | 1618 | Non-Final OA | Mar 19, 2025 |
| 18977210 | Ribociclib Tablet | Novartis AG | FUBARA, BLESSING M | 1613 | Non-Final OA | Dec 11, 2024 |
| 18773055 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | Advanced Accelerator Applications International SA | JONES, DAMERON LEVEST | 1618 | Non-Final OA | Jul 15, 2024 |
| 18664977 | COMPOSITIONS AND METHODS TO TREAT CANCER | Novartis AG | DAVIS, BRIAN J | 1614 | Non-Final OA | May 15, 2024 |
| 18701740 | PHARMACEUTICAL COMPOSITIONS | Novartis AG | CHI, AMANDA LYNN | 1613 | Non-Final OA | Apr 16, 2024 |
| 18694271 | A COMPUTER IMPLEMENTED METHOD FOR ASSESSING AND DETERMINING A COMPLEXITY LEVEL OF A CLINICAL TRIAL STUDY | Novartis AG | WEBB, JESSICA MARIE | 3683 | Non-Final OA | Mar 21, 2024 |
| 18689933 | USE OF FACTOR B INHIBITORS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Novartis AG | MCKOY, QUINCY ANDRE | 1626 | Non-Final OA | Mar 07, 2024 |
| 18687616 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | Novartis AG | BORALSKY, LUKE ALAN | 1624 | Non-Final OA | Feb 28, 2024 |
| 18687615 | BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER | Novartis AG | PACKARD, BENJAMIN J | 1612 | Non-Final OA | Feb 28, 2024 |
| 18588259 | Ribociclib Tablet | Novartis AG | FUBARA, BLESSING M | 1613 | Non-Final OA | Feb 27, 2024 |
| 18685551 | LOU064 FOR TREATING MULTIPLE SCLEROSIS | Novartis AG | CHAO, ALLEN | 1622 | Non-Final OA | Feb 22, 2024 |
| 18426461 | Novel Heteroaryl Aminopropanol Derivatives | Novartis AG | HABTE, KAHSAY | 1624 | Non-Final OA | Jan 30, 2024 |
| 18293349 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | Ptc Therapeutics, Inc. | ULLMAN, AARON RAFANAN | 1628 | Non-Final OA | Jan 29, 2024 |
| 18580781 | DOSING REGIMEN FOR AN NLRP3 INHIBITOR IN THE TREATMENT OF OSTEOARTHRITIS | Novartis AG | ROZOF, TIMOTHY R | 1625 | Non-Final OA | Jan 19, 2024 |
| 18580986 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | Novartis AG | SAEED, KAMAL A | 1626 | Non-Final OA | Jan 19, 2024 |
| 18569432 | METHOD OF TREATING AN AUTOIMMUNE HEMATOLOGICAL DISORDER | Novartis AG | OH, TAYLOR V | 1625 | Non-Final OA | Dec 12, 2023 |
| 18561444 | FORMULATIONS OF 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHENOXY)-3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-5-YL)METHYL)-5,5-DIMETHYL-1-(2-MORPHOLINOETHYL)IMIDAZOLIDINE-2,4-DIONE | Novartis AG | RAO, SAVITHA M | 1691 | Non-Final OA | Nov 16, 2023 |
| 18510836 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | Novartis AG | LEWIS, PATRICK T | 1691 | Non-Final OA | Nov 16, 2023 |
| 18559859 | DOSING REGIMENS | Novartis AG | ENGLISH, CONNOR KENNEDY | 1625 | Non-Final OA | Nov 09, 2023 |
| 18558756 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MPNST | The Johns Hopkins University | MOTEVALLI, OROD | 1628 | Non-Final OA | Nov 03, 2023 |
| 18558766 | IPTACOPAN FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME | Novartis AG | HERNANDEZ, JACKSON J | 1627 | Non-Final OA | Nov 03, 2023 |
| 18558415 | ALPELISIB FORMULATION | Novartis AG | JUSTICE, GINA CHIEUN YU | 1617 | Non-Final OA | Nov 01, 2023 |
| 18557772 | HYPERSIALYLATING CELLS | Novartis AG | BERKE-SCHLESSEL, DAVID W | 1651 | Non-Final OA | Oct 27, 2023 |
| 18557721 | METHODS FOR THE ADMINISTRATION OF ADAMTS BINDING IMMUNOGLOBULINS | Merck Patent GmbH | CHHAY, BONIRATH | 1645 | Non-Final OA | Oct 27, 2023 |
| 18555224 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | Novartis AG | ROGERS, JAMES WILLIAM | 1618 | Non-Final OA | Oct 12, 2023 |
| 18554778 | 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY | Novartis AG | BORALSKY, LUKE ALAN | 1624 | Non-Final OA | Oct 10, 2023 |
| 18483651 | Tricyclic Compounds and their Uses | Novartis AG | SEITZ, ANTHONY JOSEPH | 1629 | Non-Final OA | Oct 10, 2023 |
| 18550004 | HIGH THROUGHOUT SCREENING IN DROPLETS | Novartis AG | BUNKER, AMY M | 1684 | Non-Final OA | Sep 11, 2023 |
| 17997137 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | Novartis AG | SKOKO III, JOHN JOSEPH | 1643 | Non-Final OA | Aug 08, 2023 |
| 18363207 | NLRP3 INFLAMMASOME INHIBITORS | Novartis AG | HEES, OLIVER DRAGON | 1628 | Non-Final OA | Aug 01, 2023 |
| 18263151 | DOSAGE REGIMES FOR ANTI-CD73 AND ANTI-ENTPD2 ANTIBODIES AND USES THEREOF | Novartis AG | KAUFMAN, CLAIRE M | 1674 | Non-Final OA | Jul 27, 2023 |
| 18359830 | SILENT Fc VARIANTS OF ANTI-CD40 ANTIBODIES | Novartis AG | DAHLE, CHUN WU | 1641 | Non-Final OA | Jul 26, 2023 |
| 18015799 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | Novartis Pharma AG | MCDOWELL, BRIAN E | 1624 | Non-Final OA | Jul 21, 2023 |
| 18261523 | PHARMACEUTICAL COMPOSITION | Novartis AG | GOTFREDSON, GAREN | 1619 | Non-Final OA | Jul 14, 2023 |
| 18271192 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | Novartis Pharma AG | HAVLIN, ROBERT H | 1626 | Non-Final OA | Jul 06, 2023 |
| 18271186 | OXALAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | Novartis Pharma AG | FETTEROLF, BRANDON J | 1626 | Non-Final OA | Jul 06, 2023 |
| 18271181 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | Novartis Pharma AG | NOLAN, JASON MICHAEL | 1623 | Non-Final OA | Jul 06, 2023 |
| 18335507 | METHODS FOR THE DETECTION OF ANTI-DRUG ANTIBODIES AGAINST FACTOR XI AND/OR FACTOR XIA ANTIBODIES | Anthos Therapeutics, Inc. | LUSI, ELLIS FOLLETT | 1677 | Non-Final OA | Jun 15, 2023 |
| 18267403 | REVERSAL BINDING AGENTS FOR ANTI-NATRIURETIC PEPTIDE RECEPTOR I (NPRI) ANTIBODIES AND USES THEREOF | Novartis AG | XIAO, YAN | 1642 | Non-Final OA | Jun 14, 2023 |
| 18266189 | METHODS OF TREATING CANCER | Novartis Pharma AG | BRAUN, MADELINE E | 1624 | Non-Final OA | Jun 08, 2023 |
| 18266169 | METHODS OF TREATING CANCER | Novartis Pharma AG | WHITE, DAWANNA SHAR-DAY | 1627 | Non-Final OA | Jun 08, 2023 |
| 18266199 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | Novartis Pharma AG | BURKETT, DANIEL JOHN | 1624 | Non-Final OA | Jun 08, 2023 |
| 18266180 | METHODS OF TREATING CANCER | Novartis Pharma AG | EMCH, GREGORY S | 1678 | Non-Final OA | Jun 08, 2023 |
| 18255296 | USE OF A COMBINATION OF AN ORPHAN MOTIF AND CPG DENSITY TO CONTROL EXPRESSION OF A HETEROLOGOUS TRANSGENE | Friedrich Miescher Institute For Biomedical Research | CASH, KAILEY ELIZABETH | 1683 | Non-Final OA | May 31, 2023 |
| 18038374 | VEGF ANTAGONIST FOR USE IN METHODS FOR TREATING OCULAR DISEASES | Novartis AG | KAUFMAN, CLAIRE M | 1674 | Non-Final OA | May 23, 2023 |
| 18251913 | ANTIBODY Fc VARIANTS | Novartis AG | HOWARD, ZACHARY C | 1674 | Non-Final OA | May 05, 2023 |
| 18035470 | CD19 BINDING MOLECULES AND USES THEREOF | Novartis AG | KAUFMAN, CLAIRE M | 1674 | Non-Final OA | May 04, 2023 |
| 18035472 | ANTI-CD19 AGENT AND B CELL TARGETING AGENT COMBINATION THERAPY FOR TREATING B CELL MALIGNANCIES | Novartis AG | NATARAJAN, MEERA | 1643 | Non-Final OA | May 04, 2023 |
| 18306958 | MULTISPECIFIC ANTIBODIES TARGETING IL-13 AND IL-18 | Novartis AG | O'BRIEN, LEA S | 1646 | Non-Final OA | Apr 25, 2023 |
| 18248119 | USE OF AN ERK INHIBITOR FOR THE TREATMENT OF MYELOFIBROSIS | University of Basel | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | Non-Final OA | Apr 06, 2023 |
| 18248000 | DRUG CONTAINING DISSOLVABLE OCULAR INSERTS AND METHOD OF USING SAME | Novartis AG | FAY, ZOHREH ALEMZADEH | 1617 | Non-Final OA | Apr 05, 2023 |
| 18023217 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | Novartis AG | VU, JAKE MINH | 1618 | Non-Final OA | Feb 24, 2023 |
| 18023212 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | Novartis AG | LIU, TRACY | 1614 | Non-Final OA | Feb 24, 2023 |
| 18019469 | TREATMENT OF B CELL MALIGNANCIES | Novartis AG | KAUFMAN, CLAIRE M | 1674 | Final Rejection | Feb 02, 2023 |
| 18019467 | TREATMENT OF CLL | Novartis AG | KAUFMAN, CLAIRE M | 1674 | Final Rejection | Feb 02, 2023 |
| 18006894 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG | TOWNSLEY, SARA ELIZABETH | 1629 | Final Rejection | Jan 26, 2023 |
| 18015853 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | Novartis Pharma AG | HSU, GRACE CHING | 1627 | Non-Final OA | Jan 12, 2023 |
| 18002572 | ORAL LIQUID FORMULATIONS OF RUXOLITINIB | Novartis AG | CORNET, JEAN P | 1628 | Final Rejection | Dec 20, 2022 |
| 17925166 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | Novartis Pharma AG | SZNAIDMAN, MARCOS L | 1628 | Non-Final OA | Nov 14, 2022 |
| 17925126 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | Chinook Therapeutics Canada, Inc. | BAUER, NICOLA MARIA | 1621 | Non-Final OA | Nov 14, 2022 |
| 17997482 | ENGINEERED IMMUNOGLOBULINS | Novartis AG | NATARAJAN, MEERA | 1643 | Non-Final OA | Oct 28, 2022 |
| 18048797 | METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS | Novartis AG | JIANG, DONG | 1674 | Non-Final OA | Oct 21, 2022 |
| 17938846 | METHODS OF TREATING NEW-ONSET PLAQUE TYPE PSORIASIS USING IL-17 ANTAGONISTS | Novartis AG | JIANG, DONG | 1674 | Non-Final OA | Oct 07, 2022 |
| 17820005 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | Novartis AG | VANHORN, ABIGAIL LOUISE | 1636 | Non-Final OA | Aug 16, 2022 |
| 17759943 | PURIFICATION OF RECOMBINANTLY PRODUCED POLYPEPTIDES | Novartis AG | DEBERRY, REGINA M | 1647 | Non-Final OA | Aug 02, 2022 |
| 17853537 | Pharmaceutical Compositions Comprising Alpelisib | Novartis AG | NEAGU, IRINA | 1629 | Final Rejection | Jun 29, 2022 |
| 17789694 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | Novartis Pharma AG | SHTERENGARTS, SAMANTHA L | 1623 | Non-Final OA | Jun 28, 2022 |
| 17786347 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | Novartis AG | HILL, KEVIN KAI | 1638 | Non-Final OA | Jun 16, 2022 |
| 17785660 | PHARMACEUTICAL FORMULATIONS AND DOSAGE REGIMENS FOR FACTOR XI/XIA ANTIBODIES | Anthos Therapeutics, Inc. | KIM, YUNSOO | 1641 | Non-Final OA | Jun 15, 2022 |
| 17756106 | PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN AGMAT-POSITIVE CELLS IN LAYER 2/3 OF MOUSE CORTEX | Friedrich Miescher Institute For Biomedical Research | HILL, KEVIN KAI | 1638 | Final Rejection | May 17, 2022 |
| 17773935 | TREATMENT FOR SJÖGREN'S SYNDROME USING AN ANTI-BAFFR ANTIBODY | Novartis AG | KAUFMAN, CLAIRE M | 1674 | Non-Final OA | May 03, 2022 |
| 17754059 | RADIOLABELLED GRPR-ANTAGONIST FOR USE AS THERAGNOSTIC | Novartis AG | YOUNG, MICAH PAUL | 1618 | Final Rejection | Mar 22, 2022 |
| 17753850 | METHODS FOR RADIOLABELLING GRPR ANTAGONISTS AND THEIR KITS | Novartis AG | MEJIAS, SAMANTHA LEE | 1618 | Final Rejection | Mar 16, 2022 |
| 17642292 | GLUE DEGRADERS AND METHODS OF USE THEREOF | Novartis AG | HEITMEIER, KENDALL NICOLE | 1621 | Final Rejection | Mar 11, 2022 |
| 17640293 | THERAPEUTIC FUSION PROTEINS | Novartis AG | DEBERRY, REGINA M | 1647 | Final Rejection | Mar 03, 2022 |
| 17629286 | REGULATABLE EXPRESSION SYSTEMS | Novartis AG | LEVIN, JOEL D | 1633 | Final Rejection | Jan 21, 2022 |
| 17612280 | ANTIBODY DRUG CONJUGATES HAVING LINKERS COMPRISING HYDROPHILIC GROUPS | Novartis AG | VAN DRUFF, SYDNEY | 1643 | Non-Final OA | Nov 18, 2021 |
| 17609261 | ANTI-CD40 ANTIBODIES FOR USE IN TREATMENT OF TIDM AND INSULITIS | Novartis AG | BERHANE, SELAM | 1675 | Final Rejection | Nov 05, 2021 |
| 17484727 | Enhanced in Vivo Targeting of Site-Specific Drugs | Advanced Accelerator Applications Usa, Inc. | HARTLEY, MICHAEL G | 1618 | Non-Final OA | Sep 24, 2021 |
| 17376829 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | Novartis Pharma AG | SHTERENGARTS, SAMANTHA L | 1623 | Non-Final OA | Jul 15, 2021 |
| 17421747 | LTA4H INHIBITORS FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVA | Novartis AG | CHANNAVAJJALA, LAKSHMI SARADA | 1611 | Final Rejection | Jul 09, 2021 |
| 17292881 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG | SCHMIDT, IZABELA MARIA | 1621 | Non-Final OA | May 11, 2021 |
| 16761513 | METHOD OF TREATING HIDRADENTITIS SUPPURATIVA WITH IL-17 ANTAGONISTS | Novartis AG | DEBERRY, REGINA M | 1647 | Final Rejection | May 05, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial